Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Large Drop in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 13,032 shares, a decline of 87.0% from the February 12th total of 100,079 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 107,656 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 107,656 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.2% of the shares of the company are short sold.

Institutional Trading of Revelation Biosciences

Several large investors have recently added to or reduced their stakes in REVB. Geode Capital Management LLC acquired a new stake in shares of Revelation Biosciences during the 4th quarter valued at $27,000. Armistice Capital LLC purchased a new stake in Revelation Biosciences in the 3rd quarter worth approximately $114,000. Finally, Sabby Management LLC lifted its position in Revelation Biosciences by 214.7% in the 3rd quarter. Sabby Management LLC now owns 207,051 shares of the company’s stock worth $294,000 after buying an additional 141,262 shares in the last quarter. 12.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Revelation Biosciences in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Revelation Biosciences presently has a consensus rating of “Sell”.

Revelation Biosciences Stock Performance

Shares of REVB opened at $1.31 on Wednesday. Revelation Biosciences has a one year low of $1.19 and a one year high of $44.77. The stock has a 50-day moving average price of $2.23 and a 200 day moving average price of $4.40. The company has a market capitalization of $9.03 million, a P/E ratio of -0.02 and a beta of -0.10.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.24). As a group, equities research analysts forecast that Revelation Biosciences will post -49.33 earnings per share for the current fiscal year.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.